2011 publications

2011 publications

 

de Jonge HJM*, Woolthuis CM*, Vos A, Mulder A, van den Berg E, Kluin PM, van der Weide K, de Bont ESJM, Huls G, Vellenga E, Schuringa JJ. (2011) Gene expression profiling in the leukemic stem cell-enriched AML CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia, in press.

Woolthuis CM, de Haan G, Huls G. Aging of hematopoietic stem cells: Intrinsic changes or micro-environmental effects? Curr Opin Immunol. 2011 Jun 8. [Epub ahead of print]

Woolthuis C, Agool A, Olthof S, Slart RH, Huls G, Smid WM, Schuringa JJ, Vellenga E. Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. Bone Marrow Transplant. 2011 Jan;46(1):110-5. Epub 2010 Apr 12.

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011 Mar 17;364(11):1027-36.

Agool A, Slart RH, Kluin PM, de Wolf JT, Dierckx RA, Vellenga E. 6.F-18 FLT PET: a noninvasive diagnostic tool for visualization of the bone marrow compartment in patients with aplastic anemia: a pilot study. Clin Nucl Med. 2011 Apr;36(4):286-9.

de Jonge HJ, Valk PJ, de Bont ES, Schuringa JJ, Ossenkoppele G, Vellenga E, Huls G. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011 May 23. [Epub ahead of print]

Mega T, Lupia M, Amodio N, Horton SJ, Mesuraca M, Pelaggi D, Agosti V, Grieco M, Chiarella E, Spina R, Moore MA, Schuringa JJ, Bond HM, Morrone G. Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors. Cell Cycle. 2011 Jul 1;10(13). [Epub ahead of print]

Fatrai S, Wierenga AT, Daenen SM, Vellenga E, Schuringa JJ. Identification of HIF2{alpha} as an important STAT5 target gene in human hematopoietic stem cells. Blood. 2011 Jan 24. [Epub ahead of print]

Fatrai S, van Gosliga D, Han L, Daenen SM, Vellenga E, Schuringa JJ. KRASG12V Enhances Proliferation and Initiates Myelomonocytic Differentiation in Human Stem/Progenitor Cells via Intrinsic and Extrinsic Pathways. J Biol Chem. 2011 Feb 25;286(8):6061-70. Epub 2010 Dec 17.

Woolthuis C, Agool A, Olthof S, Slart RH, Huls G, Smid WM, Schuringa JJ, Vellenga E. Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. Bone Marrow Transplant. 2011 Jan;46(1):110-5. Epub 2010 Apr 12.

Agool A, Slart RH, Kluin PM, de Wolf JT, Dierckx RA, Vellenga E. F-18 FLT PET: A Noninvasive Diagnostic Tool for Visualization of the Bone Marrow Compartment in Patients With Aplastic Anemia: A Pilot Study. Clin Nucl Med. 2011 Apr;36(4):286-9.